DelveInsight’s “Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hypertriglyceridemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertriglyceridemia Market Forecast
Some of the key facts of the Hypertriglyceridemia Market Report:
- The Hypertriglyceridemia market size was valued approximately USD 2,400 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In November 2023, During the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, USA, Arrowhead Pharmaceuticals presented Phase II clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3). Results from the Phase II SHASTA-2 study revealed that plozasiran led to significant reductions, including a decrease in APOC3 by 79%, triglycerides (TG) by 74%, and remnant cholesterol by 65%, while increasing high-density lipoprotein (HDL)-cholesterol (HDL-C) by 68% at 24 weeks among patients with severe hypertriglyceridemia.
- According to DelveInsight’s analysis, the diagnosed prevalent cases of hypertriglyceridemia in the 7MM were estimated to be around 69,607,255 in 2022. Projections suggest that these numbers are likely to rise during the forecast period.
- In 2022, the total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM were noted to be 3,480,363. There was a notable compound annual growth rate (CAGR) observed during the study period from 2019 to 2032.
- In the European region, Germany had the largest diagnosed prevalent population of severe hypertriglyceridemia (SHTG) with 364,734 cases in 2022, followed by the UK with 278,983 cases. Conversely, Spain had the lowest diagnosed prevalent population.
- The Hypertriglyceridemia pipeline includes significant assets such as Olezarsen (ApoC-III), ARO-APOC3, Pegozafermin (BIO89-100), and others. These promising candidates, upon successful launch, are expected to drive market growth during the forecast period.
- Key Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, Eli Lilly and Company, OrsoBio, Marea Therapeutics, NorthSea Therapeutics, and others
- Key Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, LY3875383, TLC-2716, MAR001, NST-1024, and others
- The Hypertriglyceridemia epidemiology based on gender analyzed that the severity‐specific data reveal the highest number of cases were observed in moderate level of Hypertriglyceridemia
- The Hypertriglyceridemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypertriglyceridemia pipeline products will significantly revolutionize the Hypertriglyceridemia market dynamics.
Hypertriglyceridemia Overview
Hypertriglyceridemia is a condition characterized by elevated levels of triglycerides in the blood. Triglycerides are a type of fat found in the bloodstream and stored in fat cells. When levels of triglycerides are too high, it can increase the risk of various health complications, including cardiovascular disease, pancreatitis, and metabolic syndrome.
Get a Free sample for the Hypertriglyceridemia Market Forecast, Size & Share Analysis Report:
delveinsight.com/report-store/hypertriglyceridemia-market
Hypertriglyceridemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypertriglyceridemia Epidemiology Segmentation:
The Hypertriglyceridemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Hypertriglyceridemia
- Prevalent Cases of Hypertriglyceridemia by severity
- Gender-specific Prevalence of Hypertriglyceridemia
- Diagnosed Cases of Episodic and Chronic Hypertriglyceridemia
Download the report to understand which factors are driving Hypertriglyceridemia epidemiology trends @ Hypertriglyceridemia Epidemiology Forecast
Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypertriglyceridemia market or expected to get launched during the study period. The analysis covers Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypertriglyceridemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypertriglyceridemia Therapies and Key Companies
- Olezarsen: Ionis Pharmaceuticals
- Pegozafermin (BIO89-100): 89bio, Inc.
- ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
- HTD1801: Hightide Therapeutics
- LY3875383: Eli Lilly and Company
- TLC-2716: OrsoBio
- MAR001: Marea Therapeutics
- NST-1024: NorthSea Therapeutics
Discover more about therapies set to grab major Hypertriglyceridemia market share @ Hypertriglyceridemia Treatment Landscape
Hypertriglyceridemia Market Drivers
- The increasing prevalent population and increasing episodes of primary and secondary causes worldwide are likely to cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year.
Hypertriglyceridemia Market Barriers
- Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the SHTG disease market.
Scope of the Hypertriglyceridemia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, Eli Lilly and Company, OrsoBio, Marea Therapeutics, NorthSea Therapeutics, and others
- Key Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, LY3875383, TLC-2716, MAR001, NST-1024, and others
- Hypertriglyceridemia Therapeutic Assessment: Hypertriglyceridemia current marketed and Hypertriglyceridemia emerging therapies
- Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia market drivers and Hypertriglyceridemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Hypertriglyceridemia Unmet Needs, KOL’s views, Analyst’s views, Hypertriglyceridemia Market Access and Reimbursement
To know more about Hypertriglyceridemia companies working in the treatment market, visit @ Hypertriglyceridemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hypertriglyceridemia Market Report Introduction
2. Executive Summary for Hypertriglyceridemia
3. SWOT analysis of Hypertriglyceridemia
4. Hypertriglyceridemia Patient Share (%) Overview at a Glance
5. Hypertriglyceridemia Market Overview at a Glance
6. Hypertriglyceridemia Disease Background and Overview
7. Hypertriglyceridemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypertriglyceridemia
9. Hypertriglyceridemia Current Treatment and Medical Practices
10. Hypertriglyceridemia Unmet Needs
11. Hypertriglyceridemia Emerging Therapies
12. Hypertriglyceridemia Market Outlook
13. Country-Wise Hypertriglyceridemia Market Analysis (2019–2032)
14. Hypertriglyceridemia Market Access and Reimbursement of Therapies
15. Hypertriglyceridemia Market Drivers
16. Hypertriglyceridemia Market Barriers
17. Hypertriglyceridemia Appendix
18. Hypertriglyceridemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/